0000000000437573

AUTHOR

Javier Hernández-losa

0000-0003-1526-3201

showing 2 related works from this author

Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology P…

2014

Purpose The prevalence of anaplastic lymphoma kinase (ALK) gene fusion (ALK positivity) in early-stage non–small-cell lung cancer (NSCLC) varies by population examined and detection method used. The Lungscape ALK project was designed to address the prevalence and prognostic impact of ALK positivity in resected lung adenocarcinoma in a primarily European population. Methods Analysis of ALK status was performed by immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH) in tissue sections of 1,281 patients with adenocarcinoma in the European Thoracic Oncology Platform Lungscape iBiobank. Positive patients were matched with negative patients in a 1:2 ratio, both for IHC and for …

AdultMaleCancer Researchmedicine.medical_specialtyPathologyLung NeoplasmsPopulation610 Medicine & healthAdenocarcinoma of LungAdenocarcinomaGastroenterologyCohort Studies10049 Institute of Pathology and Molecular Pathologyhemic and lymphatic diseasesThoracic OncologyInternal medicinePrevalencemedicineHumansAnaplastic lymphoma kinase1306 Cancer ResearchAnaplastic Lymphoma KinaseLung cancereducationIn Situ Hybridization FluorescenceAgedNeoplasm Stagingeducation.field_of_studyLungbusiness.industryALK-PositiveReceptor Protein-Tyrosine KinasesMiddle Agedmedicine.diseaseImmunohistochemistryEuropeTreatment Outcomemedicine.anatomical_structureOncology10032 Clinic for Oncology and HematologyImmunohistochemistryAdenocarcinoma2730 OncologyFemalebusiness
researchProduct

Actualización de la recomendación para la determinación de biomarcadores en el carcinoma colorrectal. Consenso Nacional de la Sociedad Española de On…

2021

Resumen En esta actualizacion del consenso de la Sociedad Espanola de Oncologia Medica (SEOM) y la Sociedad Espanola de Anatomia Patologica (SEAP) se revisan los avances producidos en el analisis de biomarcadores en cancer colorrectal (CCR) avanzado, asi como en los marcadores de susceptibilidad del CCR hereditario y los biomarcadores moleculares del CCR localizado. Tambien se evaluan la informacion publicada recientemente sobre la determinacion imprescindible de las mutaciones de KRAS, NRAS y BRAF y la conveniencia de determinar la amplificacion del receptor del factor de crecimiento epidermico 2 (HER2), la expresion de las proteinas de la via reparadora de ADN y el estudio de las fusiones…

0301 basic medicine03 medical and health sciences030104 developmental biology0302 clinical medicine030220 oncology & carcinogenesisPathology and Forensic MedicineRevista Española de Patología
researchProduct